CANbridge Pharmaceuticals Inc.
Pharmaceutical-Manufacturing
Website
Company Tagline
To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China.
Industry Category
Business Keywords
Company Description
CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company dedicated to delivering life-changing therapeutics, with a strong foundation in China. CANbridge Pharmaceuticals Inc. focuses on accelerating the development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, addressing underserved medical needs in the region. The company is recognized as a leader in addressing orphan diseases in China.
CANbridge Pharmaceuticals Inc. operates from multiple locations, including its primary address at 4 Burlington Woods Dr, Burlington, Massachusetts 01803, US. Additional locations include 139 Main St, Cambridge, Massachusetts 02142, US; 15 Canton Road, Tsim Sha Tsui, Unit A131, 16/F, Sun Life Tower, The Gateway, Harbour City, Hong Kong, HK; No. 17 RongChuang Road, Suite 301,3F,Timeloit, Beijing, China, CN; 999 West Zhongshan Road, Suite 708, Huawen International Mansion, Shanghai, CN; and No.281, Sec. 4, Xinyi Road, Room B06, 11F, Taipei, Taiwan, TW. CANbridge Pharmaceuticals Inc. has established a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for treating rare genetic diseases. The company also holds an exclusive licensing agreement in greater China to commercialize Hunterase®, an enzyme replacement therapy for Hunter syndrome, developed by GC Pharma and marketed in numerous countries.
Furthermore, CANbridge Pharmaceuticals Inc. boasts an impressive oncology portfolio, including exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib) in greater China, alongside rights to other novel candidates. We invite the management of CANbridge Pharmaceuticals Inc. to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work and extensive capabilities.
CANbridge Pharmaceuticals Inc. est une société biopharmaceutique mondiale dédiée à la fourniture de traitements thérapeutiques qui changent la vie, avec une base solide en Chine. CANbridge Pharmaceuticals Inc. se concentre sur l'accélération du développement et de la commercialisation de produits de santé spécialisés pour les maladies orphelines et les cancers ciblés, répondant aux besoins médicaux mal satisfaits dans la région. L'entreprise est reconnue comme un leader dans la lutte contre les maladies orphelines en Chine.
CANbridge Pharmaceuticals Inc. opère à partir de plusieurs sites, dont son adresse principale au 4 Burlington Woods Dr, Burlington, Massachusetts 01803, États-Unis. Les autres sites comprennent 139 Main St, Cambridge, Massachusetts 02142, États-Unis ; 15 Canton Road, Tsim Sha Tsui, Unité A131, 16/F, Sun Life Tower, The Gateway, Harbour City, Hong Kong, HK ; No. 17 RongChuang Road, Suite 301,3F,Timeloit, Beijing, China, CN ; 999 West Zhongshan Road, Suite 708, Huawen International Mansion, Shanghai, CN ; et No.281, Sec. 4, Xinyi Road, Room B06, 11F, Taipei, Taiwan, TW. CANbridge Pharmaceuticals Inc. a établi un partenariat mondial avec WuXi Biologics pour développer et commercialiser des produits thérapeutiques exclusifs pour le traitement des maladies génétiques rares. La société détient également un accord de licence exclusif en Grande Chine pour commercialiser Hunterase®, un traitement enzymatique substitutif pour le syndrome de Hunter, développé par GC Pharma et commercialisé dans de nombreux pays.
De plus, CANbridge Pharmaceuticals Inc. dispose d'un portefeuille d'oncologie impressionnant, comprenant les droits exclusifs de développement et de commercialisation de NERLYNX® (neratinib) de Puma Biotechnology en Grande Chine, ainsi que les droits sur d'autres candidats novateurs. Nous invitons la direction de CANbridge Pharmaceuticals Inc. à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme afin de mettre en évidence davantage leur travail innovant et leurs vastes capacités.
Key Personnel / Employees
Compare Companies Side by Side
Compare CANbridge Pharmaceuticals Inc. with 3 companies in Pharmaceutical-Manufacturing
| Comparison Field |
CANbridge Pharmaceuticals...Main Company |
Drug Discovery & Dev...View Profile |
Labcorp Drug Develop...View Profile |
ULB HeLSci - Continu...View Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 0 | 0 | 2008 |
|
Company Size
|
— | 51-200 | 10,001+ | 11-50 |
|
City
|
Burlington, Massachusetts | Cleveland, Ohio | Burlington,, North Carolina | Anderlecht, Brussels Region |
|
Country
|
United States | United States | Belgium | |
|
Skills & Keywords
Comparing with main company
|
11 Total Skills
Biopharmaceutical
Orphan Diseases
Targeted Cancers
Rare Genetic Diseases
Enzyme Replacement Therapy
Oncology
Pharmaceutical Manufacturing
Biotechnology
Pharma
Rare Disease
Life Sciences
|
44 Total
44 Unique
Unique Skills:
Artificial Intelligence
Big Pharma
BioPharma
Biopharmaceuticals
BioTech
Clinical Trials
+38
|
36 Total
36 Unique
Unique Skills:
Bioanalysis
Bioassays
Biotech
Cell & Gene Therapy
Central Laboratory Services
Central Labs
+30
|
16 Total
16 Unique
Unique Skills:
Biomedical
Career Reorientation
Cell Therapy
Continuing Education
E-learning
employability
+10
|
4
Total Companies2008
Oldest Founded2
Countries103
Unique SkillsSimilar Companies
Other organizations in the same industry
Adare Pharma Solutions
Pharmaceutical-ManufacturingTransforming Drug Delivery. Transforming Lives.
Alternative Company Names
This company is also known as